Join to View Full Profile
450 Brookline AveBoston, MA 02215
Dr. Ahn is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2013 - 2017
Houston Methodist Hospital (Medical Center)Residency, Internal Medicine, 2010 - 2013
Catholic University Medical CollegeClass of 2008, M.D.
Certifications & Licensure
MA State Medical License 2021 - 2026
NH State Medical License 2023 - 2025
MD State Medical License 2017 - 2022
DC State Medical License 2013 - 2017
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- State of the art biology, progression, and clinical management of monoclonal B-cell lymphocytosis (MBL): consensus report from the Intercepting Blood Cancers Workshop ...Christine E Ryan, Inhye E Ahn, Aswin Sekar, Andrew Rawstron, Julia Almeida
Blood Cancer Journal. 2025-08-29 - Activation and exhaustion of CD8 T cells in patients with chronic lymphocytic leukemia treated with ibrutinib and pembrolizumab.Rui Mu, Katherine M Hornick, Neelam Redekar, Jonathan Chen, Pia Nierman
Journal of Immunology. 2025-08-12 - Characteristics and outcomes of patients with double refractory and double exposed chronic lymphocytic leukemia.James T Yoon, Yinglu Zhou, Mariia Mikhaleva, Daniel S Choi, Stacey M Fernandes
Blood Advances. 2025-06-10
Abstracts/Posters
- A CD19/CD3 Bispecific Antibody Induces Superior T Cell Responses Against Chronic Lymphocytic Leukemia When Combined with IbrutinibInhye E Ahn, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib Show Expansion of T-Cell Clonotypes Composed of Antitumor Cytotoxic CD8+ T-CellsInhye E Ahn, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Whole Exome Sequencing Reveals Multiple Driver Events in Chronic Lymphocytic Leukemia Patients with Acquired Ibrutinib ResistanceInhye E Ahn, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Press Mentions
Clinically Indicated Ibrutinib Interruptions Do Not Limit Long-Term Benefit in CLLJune 27th, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
